Patents by Inventor Michael J. Orwat

Michael J. Orwat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Phenylacetamides as inhibitors of rock
    Patent number: 11306081
    Abstract: The present invention provides compounds of Formula (I): Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: April 19, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael J. Orwat, Donald J. P. Pinto
  • PYRIMIDINONES AS FACTOR XIA INHIBITORS
    Publication number: 20220041601
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Application
    Filed: June 15, 2021
    Publication date: February 10, 2022
    Inventors: Andrew K. Dilger, James R. Corte, Indawati De Lucca, Tianan Fang, Wu Yang, Yufeng Wang, Kumar Balashanmuga Pabbisetty, William R. Ewing, Yeheng Zhu, Ruth R. Wexler, Donald J.P. Pinto, Michael J. Orwat, Leon M. Smith, II
  • Pyrimidinones as factor XIA inhibitors
    Patent number: 11053247
    Abstract: The present invention provides compounds of Formula (1): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: July 6, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Andrew K. Dilger, James R. Corte, Indawati De Lucca, Tianan Fang, Wu Yang, Yufeng Wang, Kumar Balashanmuga Pabbisetty, William R. Ewing, Yeheng Zhu, Ruth R. Wexler, Donald J. P. Pinto, Michael J. Orwat, Leon M. Smith, II
  • PHENYLACETAMIDES AS INHIBITORS OF ROCK
    Publication number: 20210147407
    Abstract: The present invention provides compounds of Formula (I): Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Application
    Filed: July 11, 2018
    Publication date: May 20, 2021
    Inventors: Michael J. Orwat, Donald J.P. Pinto
  • Spiroheptane salicylamides and related compounds as inhibitors of ROCK
    Patent number: 10829501
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: November 10, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Leon M. Smith, II, Vladimir Ladziata, Indawati DeLucca, Donald J. P. Pinto, Michael J. Orwat, Andrew K. Dilger, Kumar Balashanmuga Pabbisetty, Wu Yang, Scott A. Shaw, Peter W. Glunz, Manoranjan Panda
  • Factor XIa macrocycle inhibitors bearing a non-aromatic P2' group
    Patent number: 10676477
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: June 9, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yeheng Zhu, Andrew K. Dilger, William R. Ewing, Michael J. Orwat, Donald J. P. Pinto
  • LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS
    Publication number: 20200140436
    Abstract: The present application describes lactam-containing compounds and derivatives thereof of Formula I: P4-P-M-M4?? I or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.
    Type: Application
    Filed: January 8, 2020
    Publication date: May 7, 2020
    Inventors: Donald J.P. Pinto, Mimi L. Quan, Michael J. Orwat, Yun-Long Li, Wei Han, Jennifer X. Qiao, Patrick Y.S. Lam, Stephanie L. Koch
  • SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK
    Publication number: 20200131200
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Application
    Filed: January 10, 2020
    Publication date: April 30, 2020
    Inventors: Leon M. Smith, II, Vladimir Ladziata, Indawati De Lucca, Donald J.P. Pinto, Michael J. Orwat, Andrew K. Dilger, Kumar Balashnmuga Pabbisetty, Wu Yang, Scott A. Shaw, Peter W. Glunz, Manoranjan Panda
  • Spiroheptane salicylamides and related compounds as inhibitors of rock
    Patent number: 10611776
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: April 7, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Leon M. Smith, II, Vladimir Ladziata, Indawati De Lucca, Donald J. P. Pinto, Michael J. Orwat, Andrew K. Dilger, Kumar Balashanmuga Pabbisetty, Wu Yang, Scott A. Shaw, Peter W. Glunz, Manoranjan Panda
  • PYRIMIDINONES AS FACTOR XIA INHIBITORS
    Publication number: 20200055854
    Abstract: The present invention provides compounds of Formula (1): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Application
    Filed: June 25, 2019
    Publication date: February 20, 2020
    Inventors: Andrew K. Dilger, James R. Corte, Indawati De Lucca, Tianan Fang, Wu Yang, Yufeng Wang, Kumar Balashanmuga Pabbisetty, William R. Ewing, Yeheng Zhu, Ruth R. Wexler, Donald J.P. Pinto, Michael J. Orwat, Leon M. Smith, II
  • Pyrimidinones as factor XIa inhibitors
    Patent number: 10336754
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: July 2, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Andrew K. Dilger, James R. Corte, Indawati De Lucca, Tianan Fang, Wu Yang, Yufeng Wang, Kumar Balashanmuga Pabbisetty, William R. Ewing, Yeheng Zhu, Ruth R. Wexler, Donald J. P. Pinto, Michael J. Orwat, Leon M. Smith, II
  • Macrocyclic factor XIa inhibitors bearing heterocyclic groups
    Patent number: 10273236
    Abstract: The present invention provides compounds of Formula (Ia): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: April 30, 2019
    Assignee: Bristol-Myers Squibb
    Inventors: Andrew K. Dilger, James R. Corte, Indawati De Lucca, Tianan Fang, Wu Yang, Yufeng Wang, Kumar Balashanmuga Pabbisetty, William R. Ewing, Yeheng Zhu, Ruth R. Wexler, Donald J. P. Pinto, Michael J. Orwat, Leon M. Smith, II
  • Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
    Patent number: 10208021
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: February 19, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael J. Orwat, Donald J. P. Pinto, Leon M. Smith, II, Shefali Srivastava
  • SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK
    Publication number: 20190016735
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Application
    Filed: January 13, 2017
    Publication date: January 17, 2019
    Inventors: Leon M. Smith II, Vladimir Ladziata, Indawati De Lucca, Donald J.P. Pinto, Michael J. Orwat, Andrew K. Dilger, Kumar Balashanmuga Pabbisetty, Wu Yang, Scott A. Shaw, Peter W. Glunz, Manoranjan Panda
  • FACTOR XIA MACROCYCLE INHIBITORS BEARING A NON-AROMATIC P2' GROUP
    Publication number: 20190010154
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Application
    Filed: July 28, 2016
    Publication date: January 10, 2019
    Inventors: Yeheng Zhu, Andrew K. Dilger, William R. Ewing, Michael J. Orwat, Donald J.P. Pinto
  • SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS
    Publication number: 20180265494
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.
    Type: Application
    Filed: May 17, 2018
    Publication date: September 20, 2018
    Inventors: Michael J. Orwat, Donald J.P. Pinto, Leon M. Smith, II, James R. Corte, Shefali Srivastava
  • LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS
    Publication number: 20180244673
    Abstract: The present application describes lactam-containing compounds and derivatives thereof of Formula I: P4—P-M-M4??I or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.
    Type: Application
    Filed: April 30, 2018
    Publication date: August 30, 2018
    Inventors: Donald J.P. Pinto, Mimi L. Quan, Michael J. Orwat, Yun-Long Li, Wei Han, Jennifer X. Qiao, Patrick Y.S. Lam, Stephanie L. Koch
  • MACROCYCLIC FACTOR XIA INHIBITORS BEARING HETEROCYCLIC GROUPS
    Publication number: 20180222907
    Abstract: The present invention provides compounds of Formula (Ia): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Application
    Filed: April 6, 2018
    Publication date: August 9, 2018
    Inventors: Andrew K. Dilger, James R. Corte, Indawati De Lucca, Tianan Fang, Wu Yang, Yufeng Wang, Kumar Balashanmuga Pabbisetty, William R. Ewing, Yeheng Zhu, Ruth R. Wexler, Donald J.P. Pinto, Michael J. Orwat, Leon M. Smith, II
  • SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS
    Publication number: 20180201603
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.
    Type: Application
    Filed: March 12, 2018
    Publication date: July 19, 2018
    Inventors: Michael J. Orwat, Donald J. P. Pinto, Leon M. Smith, II, Shefali Srivastava
  • PYRIMIDINONES AS FACTOR XIA INHIBITORS
    Publication number: 20180186795
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Application
    Filed: February 23, 2018
    Publication date: July 5, 2018
    Inventors: Andrew K. Dilger, James R. Corte, lndawati De Lucca, Tianan Fang, Wu Yang, Yufeng Wang, Kumar Balashanmuga Pabbisetty, William R. Ewing, Yeheng Zhu, Ruth R. Wexler, Donald J.P. Pinto, Michael J. Orwat, Leon M. Smith, II